Dr. Fuchs on Angiogenesis in Gastric Cancer

Charles S. Fuchs, MD, MPH
Published Online: Thursday, February 20, 2014
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting angiogenesis in the treatment of gastric cancer.

In the AVAGAST trial, patients were randomized to chemotherapy or chemotherapy plus bevacizumab in the frontline. Results from the trial indicated a benefit to progression-free survival (PFS) and response, but no significant effect on overall survival (OS).

Fuchs says he was involved in a randomized study of ramucirumab, a monoclonal antibody against VEGFR2, compared with placebo in the second-line. Treatment with ramucirumab demonstrated significant improvement to OS and PFS, as well as a trivial toxicity profile.

Online CME Activities
Free CME from PER
Angiogenesis Inhibitors for Gastrointestinal Cancers: Update From the 2015 Gastrointestinal Cancers Symposium
Cancer Summaries and Commentaries™: Updates from San Francisco in Acute Myeloid Leukemia
Community Practice Connections: 9th Annual New York Lung Cancer Symposium®
Recap of SABCS 2014: Changes for Today and Hope for Tomorrow
More Reading
$auto_registration$